NCT05781048 2026-03-10
A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
Jiangsu HengRui Medicine Co., Ltd.
Akeso
Quanta Therapeutics
Debiopharm International SA
Hangzhou Converd Co., Ltd.